利拉鲁肽对初诊肥胖2型糖尿病患者血清nesfatin-1和炎性指标的影响  

Effects of liraglutide on level of serum nesfatin-1and inflammatory factors in newly diagnosed obese patients with type 2diabetes mellitus

作　　者：朱亭[1] 邓月珍[1] 季正香 董林[1] 成兴波 Zhu Ting;Deng Yuezhen;Ji Zhengxiang;Dong Lin;Cheng Xingbo(Department of Endocrinology &Metabolism,The Affiliated Taixing People's Hospital of Medical College,Taixing 225400,China)

机构地区：[1]扬州大学医学院附属泰兴市人民医院内分泌科,225400

出　　处：《国际内分泌代谢杂志》2018年第6期366-369,共4页International Journal of Endocrinology and Metabolism

摘　　要：目的 探讨利拉鲁肽对初诊肥胖2型糖尿病(T2DM)患者血清nesfatin-1以及炎性指标的影响.方法 选取2015年6月至2017年5月在扬州大学医学院附属泰兴人民医院内分泌科门诊新诊断的肥胖T2DM患者66例(肥胖T2DM组)以及体检中心的健康体检者40名(健康对照组),肥胖T2DM组使用利拉鲁肽皮下注射治疗3个月,比较治疗前、后血清nesfatin-1、白细胞介素-6(IL-6)、单核细胞趋化蛋白-1(MCP-1)、肿瘤坏死因子-α(TNF-α)水平、体重指数、空腹血糖、HbAlc,分析nesfatin-1与炎性指标的相关性.结果 治疗前,与健康对照组相比,肥胖T2DM组血清nesfatin-1水平明显下降(t=5.343,P<0.01),IL-6、TNF-α、MCP-1水平均显著升高(t=-13.358、-3.211、3.622,P均<0.01),且nesfatin-1与IL-6(r=-0.38,P=0.07)、MCP-1(r=-0.88,P<0.01)、TNF-α(r=-0.68,P<0.01)呈负相关;经利拉鲁肽治疗后,肥胖T2DM组空腹血糖、HbAIc、体重指数以及血清IL-6、MCP-1、TNF-α水平均较治疗前下降(f=6.735、6.702、6.314、3.622、3.897、11.191,P均<0.01),而nesfatin-1水平较治疗前升高(t=-13.560,P<0.01).结论 利拉鲁肽不仅上调肥胖T2DM患者血清nesfatin-1水平,而且具有潜在的抗炎作用.Objective To investigate the effects of liraglutide on level of serum nesfatin-1 and inflammatory factors in newly diagnosed obese patients with type 2 diabetes mellitus (T2DM).Methods Sixty-six outpatients with newly diagnosed obese T2DM (obese T2DM group) and 40 healthy subjects (healthy control group) in the physical examination center from Jun 2015 to May 2017 were enrolled in this study.The obese T2DM group received a subcutaneous injection with liraglutide for three months.Serum nesfatin-1,interleukin-6 (IL-6),monocyte chemoattractant protein-1 (MCP-1),tumor necrosis factor-(TNF-α),body mass index (BMI),fasting plasma glucose (FPG),and HbAlc were compared before and after treatment.Furthermore,the correlation of nesfatin-1 with inflammtory factors was analyzed.Results Before treatment,compared with healthy control group,serum nesfatin-1 in obese T2DM group was significantly decreased (t = 5.343,P < 0.01) and serum IL-6,TNF-α and MCP-1 were significantly increased (t =-13.358,-3.211,3.622,all P < 0.01).The level of nesfatin-1 in obese T2DM subjects was negatively correlated with the level of IL-6,MCP-1 and TNF-α (r=-0.38,P=0.07;r=-0.88,P<0.01;r =-0.68,P < 0.01).After treatment with liraglutide,the levels of FPG,HbAIc,BMI,IL-6,MCP-1 and TNF-α were significantly decreased(t =6.735,6.702,6.314,3.622,3.897,11.191,all P<0.01),while the level of nesfatin-1 was significantly increased(t =-13.560,P <0.01).Conclusion Liraglutide can not only effectively improve the level of serum nesfatin-1 in obese patients with T2DM,but also have potential anti-inflammatory effect.

关 键 词：利拉鲁肽 NESFATIN-1 炎症 2型糖尿病 肥胖 

分 类 号：R587.1[医药卫生—内分泌]